ABSTRACT
In order to exploit the specific vulnerabilities of tumors, it is urgent to identify the basis of associated defects in genome maintenance. One unsolved problem is the mechanism of inhibition of processing of DNA double-strand break repair by REV7 and its influence on DNA repair pathways. We searched for REV7-associated proteins in human cells and found FAM35A, a protein of previously unknown function. By analyzing the FAM35A sequence we discovered that FAM35A has an unstructured N-terminal region and a C-terminal region harboring three OB-fold domains similar to single-stranded binding protein RPA. Knockdown of FAM35A caused sensitivity to DNA damaging agents, and FAM35A re-localized in damaged cell nuclei.
In a BRCA1 mutant cell line, however, depletion of FAM35A increased resistance to camptothecin, suggesting that FAM35A participates in processing of DNA ends to allow more efficient DNA repair. Moreover, we found FAM35A absent in one widely used BRCA1-mutant cancer cell line (HCC1937) with anomalous resistance to PARP inhibitors. A survey of FAM35A alterations in cancer revealed that the gene is altered at the highest frequency in prostate cancers (up to 13%) and significantly less expressed in metastatic cases. The results reveal a new DNA repair factor with promise as a therapeutically relevant cancer marker.
REV7 is a multifunctional protein encoded by the MAD2L2 gene in human cells. REV7 acts as an interaction module in several cellular pathways. One of its functions is as a component of DNA polymerase ζ, where it serves as bridge between the pol ζ catalytic subunit REV3L and the REV1 protein. A dimer of REV7 binds to two adjacent sites in REV3L by grasping a peptide of REV3L with a "safety-belt" loop 1, 2 . REV7 protein is ~1000 times more abundant than REV3L 1 and has additional functions and protein partners including chromatin-associated and posttranslational modification proteins [3] [4] [5] [6] [7] [8] ). Complete ablation of REV7 gives rise to mice with defects in primary germ cells 6, 9 . Recently studies uncovered a function of REV7 as a DNA resection inhibitor, limiting genomic repair by an unknown mechanism 10, 11 . Although BRCA1 mutant cells are defective in homologous recombination, these studies found that one mode to partially restore recombination activity is by inactivation of REV7. It was proposed that REV7, together with 53BP1 and RIF1, inhibits 5' DNA end resection to promote non-homologous end joining at the expense of homologous recombination.
To investigate novel functions and pathways involving REV7, we identified proteins associated with REV7 in vivo. We report here the first analysis of a previously uncharacterized REV7-interacting protein, FAM35A. We discovered that FAM35A is a novel factor that modulates the DNA damage sensitivity of normal and BRCA1-defective cells. Our analysis reveals that the C-terminal half of FAM35A contains three OB-fold domains similar to those in the single-stranded binding protein RPA large subunit. FAM35A has a disordered N-terminal portion, containing sites of DNA damage-dependent post-translational modification. Moreover, the FAM35A gene is deleted at an unusually high rate in prostate cancers, and in at least one well-studied BRCA1-defective breast cancer cell line. FAM35A is more weakly expressed in metastatic prostate cancers, suggesting it as an important marker for outcome and therapeutic decisions.
Results and Discussion
FAM35A interacts with REV7, 53BP1, and RIF1 in vivo. To isolate proteins associated with REV7, we engineered HeLa S3 cells that stably express REV7 with a C-terminal FLAG-HA epitope tag (REV7-FH). REV7-FH was sequentially immunoprecipitated from nuclear extract using FLAG and HA antibody beads 12, 13 . This purified complex was separated by gradient gel electrophoresis and associated proteins from gel sections were identified by LC-MS/MS. We confirmed association with previously identified REV7 binding proteins including GLP 6 , G9A 6 , CAMP 8 , GTF2I 14 , POGZ 7 , and HP1α 7 ( Figure 1A and Table 1 ). A high-ranking, previously unstudied association was with the uncharacterized FAM35A protein ( Figure 1A ).
To validate the association, a reciprocal experiment was performed by constructing a HeLa S3 cell line stably expressing FAM35A with an N-terminal FLAG-HA tag (FH-FAM35A). Cells were exposed to mitomycin C (MMC, 100 ng/mL) for 18 h, or mock-exposed. Following sequential immunoprecipitation with FLAG and HA antibody beads, proteins were separated and identified by mass spectrometry ( Figure 1B ). Proteins associating with FAM35A included REV7, RIF1, BLM and TOP3A (Table 2) , with relatively more RIF1 peptides and 53BP1 identified following MMC exposure (Table 3) .
Although REV7 is known to cooperate functionally with 53BP1 to limit resection at DNA breaks, REV7 was not detected in 53BP1 immunocomplexes, and it is unknown how REV7 connects with 53BP1 in vivo 11 . To verify an association of FAM35A with 53BP1 and the additional DNA end-resection control factor RIF1, FH-FAM35A was co-transfected with GFP-RIF1 or GFP-53BP1 and expressed in 293T cells. All proteins were expressed at the predicted molecular weights ( Figure 1C , "input" lanes). Following immunoprecipitation with GFP antibody beads, FAM35A co-immunoprecipitated with recombinant RIF1 or 53BP1 (but not with the control vector, Figure 1C ). These interactions suggest that FAM35A may functionally bridge 53BP1 and REV7 in human cells FAM35A is an OB-fold protein that changes localization following DNA damage. We found FAM35A orthologs are present in vertebrate genomes, but not in invertebrates or plants. Multiple protein isoforms arising from alternative splicing are annotated in genomics databases for human (Uniprot accession number Q86V20) and mouse FAM35A. Isoforms 1 and 2 are the most common, encoding 904 and 835 amino acid proteins, respectively. They arise by differential splicing of one in-frame exon ( Fig. 1D ). Both mRNA isoforms of FAM35A are ubiquitously expressed in different cell and tissue types (gtexportal.org).
BLAST searches for sequence homologs did not reveal significant primary sequence similarity to gene products other than FAM35A. We therefore analyzed the FAM35A protein sequence using PSI-BLAST structure prediction servers. The N-terminal half of the protein is predicted to be disordered up until about residue 420 ( Figure 1D ) and this region contains posttranslational modification sites. Previous proteomic surveys identified a conserved ubiquitin modification 15 and a conserved SQ site 16 in FAM35A in which human S339 is phosphorylated after exposure to ionizing radiation or UV radiation 16 . With high significance, the C-terminal portion of FAM35A is predicted to contain three OB-fold domains structurally homologous to those in the 70 kDa subunit (RPA1) of the single-stranded DNA binding protein RPA ( Figure 1D , Supplementary Figure 1 ). The three OB folds are similar to DNA binding domain folds A, B, and C of RPA 17, 18 . OB fold domain C is predicted to include four conserved cysteine residues ( Figure 1E ) at the core of a zinc-binding ribbon, homologous to a loop in the same position in RPA ( Supplementary Figure 1) . Together, the OB folds and Zn ribbon form the elements of DNA binding and orientation enabling RPA1 to simultaneously bind to protein partners and to single-stranded DNA in an 8-10 nt binding mode [18] [19] [20] . The region including the 4-Cys Zn-ribbon identifies the domain of unknown function (PF15793) that is conserved in FAM35A homologs as annotated by the Pfam database. C-terminal helices are predicted present following OB domains A and B, in positions corresponding to helices involved in multimerization of the OBfolds in RPA subunits 17, 18 (Supplementary Figure 1 ). We constructed a human U2OS cell line stably expressing GFP-FAM35A. Cells were exposed to MMC (100 ng/mL, 24 h) or mock-exposed, and then fixed and stained with DAPI and anti-GFP. In cells exposed to DNA damaging agent, GFP-FAM35A was concentrated into foci in the nucleus (Figure 2A , Supplementary Figure 4 ), suggesting a direct involvement in DNA repair.
FAM35A-depletion sensitizes cell lines to DNA damage. The human FAM35A gene is located on chromosome 10q23.2. Three pseudogenes are also present in the human genome, two of them on 10q22 ( Figure 2B ) with high (> 98%) sequence identity to FAM35A. Precise nucleasemediated knockout of human FAM35A is therefore challenging, as simultaneous targeting of pseudogenes would likely cause chromosome rearrangements and deletion. siRNA was used to acutely deplete FAM35A from human HEK293 cells and investigate its role in DNA repair.
FAM35A-depleted HEK293 cultures were hypersensitive to MMC and etoposide, with sensitivity comparable to that conferred by depletion of Fanconi anemia FANCA and FANCD2 gene expression ( Figure 2C ). In HEK293 cells, FAM35A-siRNA did not sensitize to the PARP inhibitor olaparib ( Figure 2C ).
We investigated the impact of acute depletion of FAM35A on other markers of DNA damage responses in HEK293 cells. Cells with >5 γH2AX foci or >5 FANCD2 foci were quantified after MMC exposure (100 ng/mL, 24 h) and in control cells. MMC exposure induced cellular γH2AX foci as expected; there was no significant change in this pattern in cells depleted for FAM35A, indicating intact signaling leading to γH2AX formation ( Figure 2D ). The Fanconi anemia signaling pathway was also intact in FAM35A-depleted cells, showing about 1.5-fold more foci after MMC exposure compared to cells with siControl ( Figure 2E ).
Depletion of REV7 reduces the efficiency of non-homologous end joining (NHEJ) 10, 11 by promoting resection that channels repair of DNA double-strand breaks into homologous recombination and other pathways. Because of the association between FAM35A and the resection control factors REV7, RIF1 and 53BP1 ( Figure 1A -C), we investigated whether FAM35A depletion affects end joining, using a plasmid integration assay 10 . REV7, 53BP1 and RIF1 depletion decreased integration ratio in this assay. We confirmed efficient knockdown of FAM35A mRNA and protein in 293T cells using qPCR and immunoblot analysis ( Figure 2F ).
The plasmid integration ratio decreased significantly after FAM35A depletion ( Figure 2G ), suggesting that FAM35A is involved in modulating double-strand break repair pathway choice.
FAM35A deficiency in BRCA1-deficient cells and resistance to camptothecin and PARP
inhibitors. In BRCA1 mutant cells, REV7 depletion restores homologous recombination (HR) by restoring 5' end resection 10, 11 . We hypothesized that FAM35A depletion from BRCA1 mutant would increase resistance to a DNA strand-breaking agent. We engineered a BRCA1 mutant cell line (MDA-MB-436) expressing FAM35A shRNA. Efficient knockdown was verified by qPCR ( Figure 3A ). The FAM35A-depleted BRCA1 mutant cells and controls were assayed for sensitivity to camptothecin using a colony forming assay. FAM35A-depletion from the BRCA1 mutant cell line significantly alleviated the sensitivity to camptothecin ( Figure 3A ).
We investigated a further widely used cell line, HCC1937, which has a known inactivating mutation in BRCA1 ( Figure 3B ). Multiple studies have noted that HCC1937 is anomalously resistant to PARP inhibitors in comparison to other BRCA1 mutant cell lines, for unknown reasons [21] [22] [23] . In HCC1937, RAD51 foci (a marker of DNA end resection) are generated after DNA damage exposure 24, 25 , and homologous recombination is partially active despite BRCA1mutation 25 . We found that FAM35A mRNA expression is absent in HCC1937 cells ( Figure 3C ). FAM35A expression was present in HCC1937BL, an EBV-immortalized lymphoblastoid cell line from the same patient ( Figure 3C ). HCC1937BL is heterozygous for the BRCA1 mutation, indicating loss of heterozygosity for both FAM35A and BRCA1 in the HCC1937 mammary cancer patient.
Genomic analysis of DNA from HCC1937 and MDA-MB-436 cells showed that FAM35A DNA flanking exons 1 and 2 was not present in HCC1937 cells ( Figure 3D ). This is consistent with a deep deletion at the FAM35A locus, notated by the Cancer Cell Line Encyclopedia (CCLE, Broad Institute) in HCC1937 cells (Supplementary Figure S2 ). Reported genes related to PARP inhibitor resistance in BRCA1 mutant cells include 53BP1, MAD2L2/REV7, RIF1, BLM, CHD4 and PTIP 10,11 26, 27 . None are deleted in HCC1937 ( Figure   3B ). DNA double-strand break repair factors ATM 10 , NBS1 10 , and RNF8 10 are also preserved in HCC1937 according to the CCLE.
These data suggest an involvement of FAM35A in resection inhibition in parallel with REV7, 53BP1 and RIF1 10, 11 . Like 53BP1-depleted BRCA1 mutants 26, 28 , FAM35A-depleted BRCA1 mutant cells acquire camptothecin resistance. As HCC1937 cells can form 53BP1 foci and Mre11 foci 25 following DNA damage 24 , FAM35A appears to operate downstream of these factors and may serve as a link between 53BP1 and REV7. It is notable that the HCC1937 cell line relies on pol θ-dependent alternative end-joining for survival, perhaps unusually so for a BRCA1-defective cell line 29 . A likely explanation is that the excessive DNA end resection activity arising from the FAM35A defect channels a substantial fraction of breaks into repair by DNA polymerase θ-mediated alternative end-joining 30 .
FAM35A alterations and implications for cancers. Currently, there are two major models to account for PARP inhibitor resistance in BRCA1 mutant cells: 1) 5' resection through dysfunction of 53BP1, RIF1 or REV7 10,11 and 2) deletion of recruiters (PTIP, CHD4 and PARP1) of enzymes that degrade newly synthesized DNA 31 . Our discovery of FAM35A deletion in HCC1937 alongside reported evidence suggests a plausible mechanism of FAM35Aassociated PARP inhibitor resistance in line with the first model, via 5' resection.
We investigated the incidence of FAM35A alterations in cancer using cancer genomics databases. Mutations and copy number changes are found in FAM35A at a relatively low level (< 5% of cases) in most cancer types. Strikingly, however, prostate cancer (PCa) data show deletion of FAM35A in a high fraction (6-13%) of cases ( Figure 4A ). Prostate cancers are the only cancer type with this level of FAM35A deletion (for cancers with at least 40 cases per dataset). The PTEN gene, frequently deleted in PCa, is located on 10q23.2 about 0.5 Mb distal of FAM35A ( Figure 2B ). Some cases of FAM35A deletion are independent of PTEN deletion ( Figure 4B) . A meta-analysis of 6 datasets containing FAM35A mRNA expression data was performed to compare metastatic and primary tumors in prostate cancer. FAM35A mRNA expression is significantly reduced in metastatic prostate cancer ( Figure 4C ). In prostate cancers, deletion of FAM35A is essentially exclusive from mutation or deletion of BRCA1. From the data presented here, tumors with FAM35A deletion might be predicted to be susceptible to treatment with DNA crosslinking or double-strand break inducing agents, but not to olaparib.
Finally, we note that some other commonly used cancer cell lines harbor genetic deletion for FAM35A as annotated in the CCLE, although each must be confirmed experimentally. We found that prostate cancer cell line LNCAP clone FGC still expresses FAM35A mRNA (Supplementary Figure 2) .
The data presented here strongly implicate FAM35A in inhibition of DNA end resection following strand breakage ( Supplementary Figure 3) . In BRCA1 mutant cells, knockout of FAM35A allows recombination and/or alternative end-joining repair pathways to be utilized more efficiently, and helps explain the relative resistance to PARP inhibitors. Based on the protein interactions uncovered here and our prediction of single-stranded DNA binding activity, several possible mechanisms for FAM35A can be explored. The protein may interact directly with single stranded DNA via its OB fold domains and block activity of resection enzymes (BLM-DNA2, BLM-EXO1, and Mre11); alternatively, FAM35A could associate with BLM to prevent the interaction of BLM with DNA2 or EXO1. Immunoprecipitation assay and immunoblotting. Immunoprecipitation was performed as described 33, 34 . 48 h after transfection (for FH-FAM35A and GFP, GFP-53BP1 or GFP-RIF1) in Random plasmid integration assay. Plasmid integration assay was performed as previously described 10, 35, 36 . Plasmid transfections were performed with Polyethylenimine 25kD linear from Polysciences (cat# 23966-2) as described 37 . Briefly, 24 h after transfection (with linearized pDsRed-Monomer-Hyg-C1 (Clontech; #632495) with SmaI or XhoI) in FAM35A-depleted 293T cell lines and control cells, 1.5 x10 5 cells were plated into replicate 10 cm dishes for Hygromycin B treatment and 5 x 10 2 cells were plated into replicate 10 cm dishes for plating efficiencies.
METHODS
The next day, Hygromycin B 300 µg/ml was added to the dish, and the cells were incubated until appearance of colonies (10 to 14 days). Cells were then fixed, stained, and counted. Statistical analysis performed by unpaired t-test (p < 0.05). 
DNA damage sensitivity in FAM35A-depleted cell lines.
To analyze sensitivity to chemical DNA damaging agents, HEK293 were plated into white 96-well plates (1,250 cells/well). The next day, various concentrations of MMC, etoposide and olaparib were added to the wells, and the cells were incubated for 48 h. The cells were lysed, a reagent that luminesces in the presence of ATP was added (ATPLite One Step, Perkin Elmer). Luminescence was measured using a plate reader (Biotek Synergy II) and normalized to undamaged control. For the clonogenic assay, 1.5 x 10 5 cells were plated in 10 mm culture plates and incubated for 24 h prior to DNA damage induction. Groups of plates were exposed to camptothecin (20 nM). After 24 h, medium was changed and cells were incubated until appearance of colonies (14 to 21 days). Cells were then fixed, stained, and counted. Statistical analysis performed by unpaired t-test (p < 0.05).
Foci analysis in U2OS cells stably expressing GFP-FAM35A and FAM35A-depleted cell
lines. Immunofluorescence photos were taken on a Leica DMI6000B microscope as described previously 38 . The cells were plated into an 8-well chamber slide; the following day, cells were fixed with paraformaldehyde after MMC treatment (100 ng/ml 24 h) and stained for DAPI and GFP 33 . To measure the formation of DNA double-strand breaks and downstream signaling, Quantitative PCR (qPCR) assay. Total RNA was extracted using RNeasy Mini Kit (Qiagen) following manufacturer's protocol including on-column DNase treatment. Total RNA (1 µg) was used as template to synthesize cDNA with the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher). qPCR was then performed on the ABI 7900HT Fast Real-Time PCR System (Applied Biosystems). TaqMan primers and the probe sets for hFAM35A were purchased from Thermo Fisher (assay ID Hs04189036_m1). The absolute quantity (AQ) of transcripts for hFAM35A was determined using the generated standard curves. Standard curves for each gene were determined using the plasmid pRSFDuet-1 carrying one of hFAM35A. Each reaction was performed in triplicate.
Bioinformatics. Analysis of predicted protein disorder used the DisEMBL (http://dis.embl.de), Pondr (http://pondr.com) and Phyre2 web-based servers 42 . Protein structure prediction was cross-checked using multiple tools. Several structure prediction servers identified models corresponding to OB domain A. The ModWeb server for (https://modbase.compbio.ucsf.edu) predicts high confidence similarity (sequence identify 18%) of FAM35A residues corresponding to the OBA fold with PDB code 2K50 (Methanobacterium thermoautotrophicum RPA protein OB fold) and other with other RPA models. SwissModel (https://swissmodel.expasy.org/) located homology of FAM35A 904 aa isoform residues 583-735 (OB fold B) with human RPA1 OB-fold PDB code 1FGU. When the C-terminal 480 amino acids of FAM35A were submitted to Phyre2 for structure prediction, the highest scoring template was PDB code 4GOP (71% coverage, 99.4% confidence). OB folds A, B, and the first part of OB folds C were modeled from 4GOP. The OB fold C model and is consistent with a partial OB fold predicted for FAM35A residues 736-836, PDB code 3U50.
Cancer genome data and Cancer Cell Line Encyclopedia data was accessed from the cBioPortal for Cancer Genomics 43 . Oncomine 44 (www.oncomine.com) was used for metaanalysis of 6 datasets containing FAM35A mRNA expression data (mostly microarrays) with comparisons between metastatic and primary tumor in prostate cancer. Total patient numbers and detailed information regarding published datasets and associated publications are indicated in Figure 4B . Table 1 Footnote: GTF2I (TFII-I) is likely a non-significant association as it is an abundant protein frequently found in control experiments with agarose supports and Flag-His tags (www.crapome.org), but it is included here for reference, as it was previously reported to interact with REV7 (ref 14 ). Table 3 Footnote: Proteins from gel sections were identified by LC-MS/MS. The gel sections were approximately equal size with the exception of a wider segment for the FAM35A bait. Ku70 and Ku80 may be non-significant associations as they are found frequently in control experiments with agarose supports and Flag-His tags (www.crapome.org), but they are included here as they were not detected with significance in the complex from non-damaged cells ( Table  2 ). Bottom right is the colony count. Data represent mean ± SEM. n=3. ns: not significant, (*) P <
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